Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215357 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
A Phase 2 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01215357: Completed Phase 2 study, sponsored by Emalex Biosciences.
NCT01215357 is a Phase 2 study that has completed, run by Emalex Biosciences. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01215357, a Phase 2 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
Primary Outcome
This scale assesses the severity of gambling urges and gambling behaviors. The study anticipates that there will be a reduction in either or both of these assessments. The range is from a minimum of 0 to a maximum of 40, where zero means no gambling urges occurred.
Interventions
- DRUG Ecopipam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01215357 record still lists
NCT01215357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Ecopipam is the first listed.
NCT01215357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01215357 about?
NCT01215357 is a clinical study titled "Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble". This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
What is the current status of trial NCT01215357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2010-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01215357?
The interventions under investigation include: Ecopipam (DRUG).
Who is sponsoring clinical trial NCT01215357?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01215357's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia